Navigation Links
Clinical Immunology Society Appoints Vincent Bonagura, MD as Editor-in-Chief of the Journal of Clinical Immunology
Date:3/11/2013

Milwaukee, WI (PRWEB) March 11, 2013

The Clinical Immunology Society (CIS) is pleased to announce that Dr. Vincent Bonagura has been selected to serve as the new Editor-in-Chief of the Journal of Clinical Immunology (JoCI) for a five-year term beginning February 1, 2013. Dr. Bonagura is the Chief of the Division of Allergy and Immunology and the Jack Hausman Professor of Pediatrics at the Alexandra and Steven Cohen Children's Medical Center of the North Shore-Long Island Jewish Health System in New York, where he also directs the Jeffrey Modell Foundation Diagnostic Center and the Laboratory of Host Defense. He is also Professor of Molecular Medicine at the Feinstein Institute for Medical Research at North Shore - Long Island Jewish Health System. His research interests include virus infections, autoimmunity and primary immune deficiency; and editorial experience has been with the Annals of Allergy and Immunology, Clinical and Diagnostic Laboratory Immunology, and Clinical Immunology.

"We're very excited to have Dr. Bonagura involved with the journal and I'm certain that under his leadership, we will continue to advance the visibility and reputation of the JoCI and CIS," said CIS President, Lawrence B. Schwartz, MD PhD.

In addition, Dr. Jean-Laurent Casanova has accepted the position of Deputy Editor. Jean-Laurent Casanova, MD PhD received his medical degree from the Université Paris Descartes in 1987. After receiving training at the Pasteur Institute in Paris and the Ludwig Institute for Cancer Research in Lausanne, Switzerland, he received his PhD in immunology from the Université Pierre et Marie Curie in 1992. Following a residency in pediatrics, he completed a clinical fellowship in the pediatric immunology-hematology unit of the Necker Medical School in Paris. In 1999, he was appointed a professor of pediatrics at Necker, where, with Dr Laurent Abel, he cofounded and co-directe
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. An Evaluation of Clinical Trial Quality in Russia and Ukraine, new webinar hosted by Xtalks
2. Genomas Expands Personalized Medicine Business with Clinical Laboratory Licenses in New York, Florida, California
3. Macrogen Corp. Announces the Inception of Macrogen Clinical Laboratory (MCL)
4. PhUSE Announces Open Source Repository of Clinical Trial Informatics Analysis Code
5. QIAGEN Unveils Sample-to-Result Next-Generation Sequencing Workflow Designed for Clinical Research and Diagnostics
6. NeoClinical Launches Neo PayPerPatient Clinical Trial Recruitment
7. Eastern Clinical Trials Russia CRO Passes EMA Inspection
8. ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
9. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
10. PROLOR Biotech To Present New Preclinical Data On Its Long-Acting Clotting Factor VIIa At Leading European Scientific Conference
11. Cutting the Cost of Clinical Research: The Solution Comes from Russia, New Xtalks Webinar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014  Having the right people at the table ... business growth and achieving clinical and operational goals. The ... Summit, July 20-22, 2014, in San Diego ... and healthcare experts discussing how partnerships have positively impacted ... & Chief Executive Officer of Cape Regional Medical Center ...
(Date:7/23/2014)... 2014 - Valentis ... Trendlines Agtech , announced it has signed an ... leading agricultural thermoplastics applications companies. ... combines nanocrystalline cellulose (NCC), a biodegradable, transparent material ... to produce highly improved polymeric films. Used as ...
(Date:7/23/2014)... -- regulated information -- UCB today announced an important ... positive topline results from the latest Phase 3 ... to evaluate the efficacy and safety of ... compared to placebo, as adjunctive treatment in adult ... controlled despite treatment with one or two concomitant ...
(Date:7/23/2014)... 2014  Sofinnova Ventures, a Menlo Park ... of Sofinnova Venture Partners IX, L.P. at the hard ... initial fund target of $425 million. Sofinnova ... Consistent with recent funds, SVP IX will provide capital ... along with select investments in earlier stage opportunities. Investments ...
Breaking Biology Technology:MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Sofinnova Raises $500 Million Biotech Venture Fund 2
... Entomologists at the University of California, Riverside working on ... of compounds that could pave the way for developing inexpensive ... other deadly tropical diseases. When fruit flies undergo stress, ... a warning to other fruit flies that danger or predators ...
... HARBIN, China, Aug. 26 ... One Medical" or "the Company") (Nasdaq: ... over-the-counter,drugs in the People,s Republic of China ("PRC"), ... been raised with respect to financial reports filed,with ...
... , PARIS, August 26 , - Net Profit Up 11%, - Strong Research ... The Board of Directors, meeting on 25 August 2009 under the chairmanship,of Albert Saporta approved the 2009 half year financial ... 08/07 H1 2009, ... Var.% %CA, Sales ...
Cached Biology Technology:Discovery of natural odors could help develop mosquito repellents 2Discovery of natural odors could help develop mosquito repellents 3China Sky One Medical, Inc. Responds to Concerns Regarding Filed Financial Reports 2China Sky One Medical, Inc. Responds to Concerns Regarding Filed Financial Reports 3STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations 2STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations 3STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations 4
(Date:7/23/2014)... The U.S. Environmental Protection Agency (EPA) today announced ... University of Massachusetts Amherst School of Public Health ... $700,000 Science to Achieve Results (STAR) grant to ... Native subsistence hunters in subarctic North America to ... and to provide culturally-relevant recommendations for mitigation. , ...
(Date:7/23/2014)... Mass. Honey bees, especially the young, are highly ... work together to maintain temperatures within a narrow range. ... biologist at Tufts University,s School of Arts and Sciences, ... excess heat within a hive in process similar to ... blood vessels and skin. , "This study shows ...
(Date:7/23/2014)... cultured from cystic fibrosis patients, scientists at the UNC ... have shown that a new CF drug counteracts the ... The finding, published today in the journal Science ... becomes unstable and loses its ability to function properly ... research offers several insights into how novel CF pharmacotherapies ...
Breaking Biology News(10 mins):Studying impacts of indoor air pollution on tribal communities 2Studying impacts of indoor air pollution on tribal communities 3How honey bees stay cool 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 4
... in extreme cold, scientists no longer have to go ... Bacteria previously isolated from polar climates, and have properties ... been isolated from soil in temperate environments. , Professor ... have developed a technique to isolate bacteria which have ...
... the four bacterial surface proteins that generate the ... University of Chicago have created a vaccine that ... strains of Staphylococcus aureus, the most common cause ... of community-associated illness. , The vaccine protected ...
... The repeated copying of a small segment of DNA in ... to the transition of ancient animals from sea to land, ... discovery is "tantalizing evidence" that copied DNA elements known as ... the director of the research, Howard Hughes Medical Institute investigator ...
Cached Biology News:MRSA vaccine shows promise in mouse study 2MRSA vaccine shows promise in mouse study 3Mobile DNA part of evolution's toolbox 2Mobile DNA part of evolution's toolbox 3Mobile DNA part of evolution's toolbox 4
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
JAB1 Immunogen: Synthetic peptide, conjugated to KLH, corresponding to residues S(201) E Y Q T I P L N K I E D F G V(216) of human JAB1. The sequence is identical in mouse and rat. Storage: -...
Hamartin/TSC1 (1B2) Mouse mAb Ship: Hot Store: -20 C...
Blank Calibration Particles, 3.0-3.4 mu m 5 ml...
Biology Products: